EXPE
81
-2
CSX
43
2
WY
39
3
JWN
55
-2
BIIB
42
2
COF
47
2
LYB
29
6
MNST
51
2
AES
50
3
MDLZ
36
2
TGNA
45
-2
SLG
38
3
RL
73
-3
BRK.B
22
2
DVN
16
2
ADSK
59
-3
PFG
28
-2
ABBV
46
6
AON
32
4
VZ
30
5
EXPE
81
-2
CSX
43
2
WY
39
3
JWN
55
-2
BIIB
42
2
COF
47
2
LYB
29
6
MNST
51
2
AES
50
3
MDLZ
36
2
TGNA
45
-2
SLG
38
3
RL
73
-3
BRK.B
22
2
DVN
16
2
ADSK
59
-3
PFG
28
-2
ABBV
46
6
AON
32
4
VZ
30
5
Financhill
Back

Actinium Pharmaceuticals 10K Form

Sell
29

ATNM
Actinium Pharmaceuticals

Last Price:
$1.32
Seasonality Move:
32.49%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ATNM News And Ratings

See the #1 stock for the next 7 days that we like better than ATNM

ATNM Financial Statistics

Sales & Book Value

Annual Sales: $81K
Cash Flow: $-12M
Price / Cash Flow: 0
Annual Sales: $1.22
Price / Book: 1.03

Profitability

EPS (TTM): -1.39000
Net Income (TTM): $-40.9M
Gross Margin: $0
Return on Equity: -95.08%
Return on Assets: -50.26%

Actinium Pharmaceuticals Earnings Forecast

Key Actinium Pharmaceuticals Financial Ratios

  • The Selling, General & Administrative Expenses for ATNM have been equal to 16,458.02% of Gross Profit Margin.
  • The Research & Development expenses have been 47,740.74% of Revenue.
  • The Interest Expense is -0.02% of Operating Income.
  • Per Share Earnings over the last 18 years have been positive in 9 years.

Actinium Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: ATNM
CUSIP: 00507W
Website: actiniumpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.21
Quick Ratio: 9.03

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ATNM Technical Analysis vs Fundamental Analysis

Sell
29
Actinium Pharmaceuticals (ATNM) is a Sell

Is Actinium Pharmaceuticals a Buy or a Sell?